EpiVacCorona is a COVID-19 candidate vaccine developed by FBRI SRC VB VECTOR, Rospotrebnadzor, Koltsovo. It is a peptide type of candidate vaccine, based on the protein subunit platform. This COVID-19 candidate vaccine was in Phase I/Phase II evaluation. On October 14, 2020, regulatory approval for EpiVacCorona in Russia was announced.
|Link||Tested on||Impact factor||Notes||Publication date||DB entry date|
|Draft landscape of COVID-19 candidate vaccines||Healthy adults||Oct/15/2020||Oct/16/2020|
|ID||Title||Status||Phase||Start date||Completion date|
|NCT05021016||Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and Above||Completed||Phase 3||Nov/19/2020||Jan/30/2021|
|NCT04780035||Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19||Active, not recruiting||Phase 3||Nov/18/2020||Sep/01/2021|
|NCT04527575||Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19||Active, not recruiting||Phase 1|Phase 2||Jul/27/2020||May/01/2021|